Iksuda Therapeutics Ltd.
Clinical trials sponsored by Iksuda Therapeutics Ltd., explained in plain language.
-
New drug IKS03 aims to shrink Hard-to-Treat lymphomas
Disease control Recruiting nowThis early-phase trial tests a new drug called IKS03 in about 140 adults with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. IKS03 is designed to seek out and attack cancer cells while sparing healthy ones. The main goals are to find the safest d…
Phase: PHASE1 • Sponsor: Iksuda Therapeutics Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New HER2-Targeting drug shows promise in early trial for advanced cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called IKS014 in people with advanced HER2-positive solid tumors, including breast, stomach, and gastroesophageal cancers. The drug is designed to deliver a cancer-killing agent directly to HER2-positive tumor cells. The main goals are to f…
Phase: PHASE1 • Sponsor: Iksuda Therapeutics Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC